For example, upregulation or deletion of BANK1 was found to affect treatment outcomes in a clinical trial of irinotecan combined with rituximab for cell lymphoma, which may be related to the intervention of immune inflammatory mechanisms by drugs affecting BANK1 expression (Wang et al., 2022; Yang et al., 2018); A study on the mechanism of epithelial-mesenchymal transition and CDK4/6 inhibitor resistance in breast cancer found that CADM2 expression affects disease progression and drug efficacy, and its expression may be indirectly affected by quercetin (Li et al., 2024). Here, CADM2 is linked to breast carcinoma.